Product Pathways - Development
StemLight™ Pluripotency Surface Marker Antibody Kit #9094
|Kit Includes||Quantity||Applications||Reactivity||MW (kDa)||Isotype|
|SSEA4 (MC813) Mouse mAb #4755||40 µl||IF-IC F||H||N/A||Mouse IgG3|
|TRA-1-60(S) (TRA-1-60(S)) Mouse mAb #4746||40 µl||W IHC-P IF-IC F||H||200-400||Mouse IgM|
|TRA-1-81 (TRA-1-81) Mouse mAb #4745||40 µl||IHC-P IF-IC F||H||200-400||Mouse IgM|
Reactivity Key: H=Human
Species enclosed in parentheses are predicted to react based on 100% sequence homology.
Specificity / Sensitivity
TRA-1-60(S) (TRA-1-60(S)) Mouse mAb detects endogenous levels of the neuraminidase-sensitive TRA-1-60 antigen. TRA-1-81 (TRA-1-81) Mouse mAb detects endogenous levels of TRA-1-81 antigen. SSEA4 (MC813) Mouse mAb detects endogenous levels of SSEA4 antigen.
The StemLight™ Surface Marker Kit contains a panel of antibodies for the detection of antigens that are specifically expressed on the surface of human pluripotent cells. The kit can be used to track the pluripotent potential of human embryonic stem (ES) or induced pluripotent (iPS) cells. The loss of these markers indicates a loss of pluripotency or differentiation of the culture. The kit components are pre-optimized for parallel use in immunofluorescent analysis.
Source / Purification
Monoclonal antibodies are produced by immunizing animals with human embryonic carcinoma 2102Ep cl.2A6 cells.
Pluripotency is the ability of a cell to differentiate into cell types of the three germ layers, the endoderm, ectoderm, and mesoderm. It is a property shared by embryonic stem cells, embryonic carcinoma, and induced pluripotent cells.SSEA4, TRA-1-81, and TRA-1-60 antibodies recognize antigens expressed on the cell surface of all pluripotent cells. SSEA4 recognizes a glycolipid carbohydrate epitope (1). TRA-1-60(S) and TRA-1-81 antibodies recognize different proteoglycan epitopes on variants of the same protein, podocalyxin (2). These epitopes are neuraminidase sensitive and resistant, respectively. Reactivity of SSEA4, TRA-1-81 and TRA-1-60 antibodies with their respective cell surface markers are lost upon differentiation of pluripotent cells, corresponding with a loss of pluripotent potential (3).
- Henderson, J.K. et al. (2002) Stem Cells 20, 329-37.
- Draper, J.S. et al. (2002) J Anat 200, 249-58.
- Schopperle, W.M. and DeWolf, W.C. (2007) Stem Cells 25, 723-30.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
* Product-specific protocol.
For Research Use Only. Not For Use In Diagnostic Procedures.